A nurse is educating a patient with systemic lupus erythematosus. Which medication is commonly prescribed to manage SLE symptoms and decrease exacerbations?

Choice A rationale This antimalarial medication is a cornerstone in managing systemic lupus erythematosus by inhibiting the stimulation of toll-like receptors and reducing the production of inflammatory cytokines. It is primarily used to control skin rashes, joint pain, and fatigue while significantly reducing the frequency of disease flares. Clinical evidence suggests it also provides a long-term survival benefit and prevents organ damage accrual in patients with chronic autoimmune responses. Choice B rationale This monoclonal antibody specifically targets B-lymphocyte stimulator proteins to reduce the activity of B cells contributing to the autoimmune response in lupus. While it is an approved adjunct treatment for active, autoantibody-positive systemic lupus erythematosus, it is generally reserved for patients who do not respond adequately to standard therapies. It is not considered the most common first-line systemic agent compared to the widespread and foundational use of antimalarial drugs in this population. Choice C rationale Nonsteroidal anti-inflammatory drugs are frequently utilized in lupus management to alleviate musculoskeletal pain, pleurisy, and fever by inhibiting cyclooxygenase enzymes and prostaglandin synthesis. However, these medications only provide symptomatic relief for minor manifestations and do not modify the underlying disease course or prevent major organ exacerbations. Their use is often limited by potential side effects including gastrointestinal irritation, renal impairment, and increased cardiovascular risk in patients with systemic inflammation. Choice D rationale This folate antimetabolite acts as a potent immunosuppressant by interfering with DNA synthesis and cellular proliferation, particularly in rapidly dividing immune cells. It is often employed in lupus cases involving significant arthritis or skin disease that remains refractory to antimalarials. While effective for controlling inflammation, it carries a higher risk profile than first-line agents, necessitating frequent monitoring of liver function tests and complete blood counts to detect potential hepatotoxicity or bone marrow suppression.